


# How to Do Echo in a Multimodality Approach to Assess the Risk of Sudden Death: A Consensus Statement of the Italian Society of Echocardiography and Cardiovascular Imaging

Antonio De Luca\*, Jacopo Giulio Rizzi, Thomas Caiffa<sup>1</sup>, Massimo Zecchin, Matteo Cameli<sup>2\*</sup>, Eustachio Agricola<sup>3\*</sup>, Maurizio Cusmà Piccione<sup>4\*</sup>, Roberta Manganaro<sup>4\*</sup>, Andrea Barison<sup>5</sup>, Gianluca Di Bella<sup>4</sup>, Gianfranco Sinagra, Concetta Zito<sup>4\*</sup>

Cardiothoracovascular Department, Division of Cardiology, Azienda Sanitaria Universitaria Giuliano Isontina and University of Trieste, <sup>1</sup>Department of Paediatrics, Institute for Maternal and Child Health IRCCS 'Burlo Garofolo', Trieste, <sup>2</sup>Department of Medical Biotechnologies, Division of Cardiology, University of Siena, Siena, <sup>3</sup>Unit of Cardiovascular Imaging, IRCCS San Raffaele Hospital, Milan, <sup>4</sup>Department of Clinical and Experimental Medicine, University of Messina, Messina, <sup>5</sup>Cardiothoracic Department, Fondazione Toscana Gabriele Monasterio and Scuola Superiore Sant'Anna, Pisa, <sup>6</sup>Department of Women's and Children's Health, Pediatric Cardiology Unit, University Hospital of Padua, Padua, <sup>7</sup>Cardiology Unit, Infermi Hospital, Rimini, Italy

\*This document was written by members of the 2024-2026 SIECVI Scientific Documents Committee and reviewed by Giovanni Di Salvo<sup>6</sup>, Giovanna Di Giannuario<sup>7</sup>, Scipione Carerj<sup>4</sup> on behalf of the 2024-2026 SIECVI Board

## Graphical Abstract



Risk stratification for sudden cardiac death (SCD) is a multiparametric process that integrates the data from family history, clinical evaluation, electrocardiographic findings, arrhythmic burden, and cardiovascular imaging. Echocardiography is the first-line imaging modality for both diagnosis and risk stratification of cardiovascular diseases associated with SCD. Advances in echocardiography and multimodality imaging have identified a number of parameters with proven prognostic value in SCD risk stratification.

CMR = Cardiac magnetic resonance, CT = Computed tomography, ECG = Electrocardiogram, ECHO = Echocardiography

**Keywords:** Cardiac magnetic resonance, echocardiography, multimodality imaging, risk stratification, sudden death

**Address for correspondence:** Dr. Antonio De Luca, Cardiothoracovascular Department, Division of Cardiology, Ospedale di Cattinara - Polo Cardiologico, Via Valdoni 7, Trieste 34149, Italy. E-mail: deluca.antonio.md@gmail.com

This is an open access journal, and articles are distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 License, which allows others to remix, tweak, and build upon the work non-commercially, as long as appropriate credit is given and the new creations are licensed under the identical terms.

**For reprints contact:** WKHLRPMedknow\_reprints@wolterskluwer.com

**Submitted:** 14-May-2025

**Revised:** 06-Jun-2025

**Accepted:** 23-Jun-2025

**Published:** 30-Jul-2025

**How to cite this article:** De Luca A, Rizzi JG, Caiffa T, Zecchin M, Cameli M, Agricola E, *et al.* How to do echo in a multimodality approach to assess the risk of sudden death: A consensus statement of the Italian society of echocardiography and cardiovascular imaging. *J Cardiovasc Echography* 2025;35:183-92.

### Access this article online

Quick Response Code:



**Website:**  
<https://journals.lww.com/JCEG>

**DOI:**  
10.4103/jcecho.jcecho\_50\_25

## INTRODUCTION

Despite significant advances in knowledge, risk stratification, and treatment of cardiovascular diseases in recent years, sudden cardiac death (SCD) remains a major clinical and public health problem. SCD is defined as a sudden, unexpected death resulting from the abrupt cessation of cardiac activity.<sup>[1]</sup> SCD accounts for approximately 50% of all cardiovascular-related deaths, with up to 50% being the first manifestation of underlying heart disease.<sup>[1]</sup> The estimated annual incidence of SCD ranges from 30 to 125 cases per 100,000 person-years, markedly increasing with age and occurring more frequently in men.<sup>[1]</sup> In younger individuals, SCD is most commonly caused by cardiomyopathies and primary electrical disorders. In contrast, for those over 35 years old, coronary artery disease (CAD), particularly acute coronary syndromes, accounts for about half of the cases. In the elderly, the primary causes include acute and chronic CAD, valvular heart disease, and heart failure.<sup>[1]</sup>

While indications for the secondary prevention of SCD are well established for patients with a history of cardiac arrest or major ventricular arrhythmias, effectively identifying those at high risk for primary prevention remains a relevant issue in clinical practice.<sup>[1]</sup>

Several clinical and noninvasive risk markers have been proposed for arrhythmic risk stratification across different conditions. Among these, multimodality imaging plays a central role in identifying individuals at increased risk of SCD.<sup>[1-3]</sup>

Echocardiography, thanks to its noninvasiveness, wide accessibility and repeatability, is the first-line imaging modality for diagnosis and risk stratification of several conditions associated with SCD, allowing the evaluation of cardiac function and the detection of structural cardiovascular disease [Tables 1-3].<sup>[1,2]</sup>

Assessment of left ventricular ejection fraction (LVEF) remains, to date, one of the main risk stratification parameters and continues to play a crucial role in guiding the primary prevention of SCD, particularly when severely reduced.<sup>[1,2]</sup>

In addition to LVEF, emerging echocardiographic parameters – such as left ventricular global longitudinal strain (GLS) and mechanical dispersion (MD) assessed through speckle-tracking technique – have been associated with an increased risk of major ventricular arrhythmias and SCD in both ischemic and Non-Ischemic Heart disease.<sup>[1,4,7,8]</sup>

Cardiac magnetic resonance (CMR) is the gold standard for the evaluation of biventricular size and function, while enabling noninvasive tissue characterization. Its role in risk stratification for major ventricular arrhythmias and SCD is growing.<sup>[1,2]</sup> Notably, CMR is able to detect myocardial fibrosis, mainly through late gadolinium enhancement technique, disclosing the arrhythmic substrate within

**Table 1: Echocardiographic diagnostic criteria of cardiovascular conditions associated with sudden cardiac death**

<b>DCM</b>	
LVEDD (mm)	Males >58 Females >52
LVEDV (mL/m <sup>2</sup> )	Males ≥75 Females ≥62
LVEF <50%	
<b>ARCV</b>	
Regional RV akinesia, dyskinesia, or aneurysm and 1 of the following (end-diastole): PLAX RVOT ≥32 mm (or PLAX/BSA ≥19 mm/m <sup>2</sup> ) or PSAX RVOT ≥36 mm (or PSAX/BSA ≥21 mm/m <sup>2</sup> ) or fractional area change ≤33% (major criteria)	
Regional RV akinesia or dyskinesia and 1 of the following (end-diastole): PLAX RVOT ≥29–<32 mm (PLAX/BSA ≥16–<19 mm/m <sup>2</sup> ) or PSAX RVOT ≥32–<36 mm (PSAX/BSA ≥18–<21 mm/m <sup>2</sup> ) or fractional area change >33%–≤40% (minor criteria)	
<b>HCM</b>	
LV wall thickness >15 mm (or z-score >2 in Children) or ≥13 mm in adult first-degree relatives; consider the diagnosis if LV wall thickness 13–14 mm in the presence of other abnormalities, such as family history, genetic findings, and ECG abnormalities	
<b>Obstructive HCM</b>	
Doppler evaluation of LVOTO at rest, during Valsalva maneuver, in the sitting and semi-supine positions, and then on standing if no gradient is provoked (severe if peak pressure gradient ≥50 mmHg)	
<b>RCM</b>	
Restrictive LV and/or RV pathophysiology in the presence of normal or reduced diastolic volumes (of one or both ventricles), normal or reduced systolic volumes, and normal ventricular wall thickness	
<b>TOF</b>	
Ventricular septal defect Pulmonary stenosis Overriding aorta RV hypertrophy	
<b>ccTGA</b>	
Atrio-ventricular and ventriculo-arterial discordance	
<b>D-TGA</b>	
Pulmonary artery arising from the left ventricle Aorta arising from the right ventricle	
<b>Ebstein anomaly</b>	
Apical displacement of septal and posterior tricuspid valve leaflets (>8 mm/m <sup>2</sup> ) Atrialized right ventricle	
<b>Congenital coronary artery anomalies</b>	
AAOCA ACAPA	
<b>Mitral valve prolapse</b>	
Systolic displacement of one or both mitral leaflets ≥2 mm above the plane of the mitral annulus in the sagittal view	
<b>MAD</b>	
Separation between the ventricular myocardium and the mitral annulus supporting the posterior mitral leaflet, in both systole and diastole	
<b>Severe aortic valve stenosis</b>	
Aortic valve area ≤1 cm <sup>2</sup> (or ≤0.6 cm <sup>2</sup> /m <sup>2</sup> ) with or without mean gradient ≥40 mmHg and peak aortic velocity ≥4.0 m/s	

*Contd...*

**Table 1: Contd...**


Aortic root and ascending aorta dilatation

Aortic root dilatation: >40 mm in males, >34 mm in females or >22 mm/m<sup>2</sup>

Ascending aorta dilatation: >40 mm in males, >36 mm in females or >22 mm/m<sup>2</sup>

Aortic aneurysm: Diameter >1.5 times (>50%) larger than the predicted value

AAOCA=Anomalous aortic origin of a coronary artery, ACAPA=Anomalous coronary artery from the pulmonary artery, ccTGA=Congenitally corrected transposition of the great arteries, D-TGA=Dextro-transposition of the great arteries, ECG=Electrocardiogram, LV=Left ventricular, LVEDD=Left ventricular end-diastolic diameter, LVEDV=Left ventricular end-diastolic volume, LVEF=Left ventricular ejection fraction, LVOTO=Left ventricular outflow tract obstruction, PLAX=Parasternal long axis, PSAX=Parasternal short axis, RV=Right ventricular, RVOT=Right ventricular outflow tract, RCM=Restrictive cardiomyopathy, MAD=Mitral annular disjunction, HCM=Hypertrophic cardiomyopathy, ARCV=Arrhythmogenic right ventricular cardiomyopathy, AV=Atrio-ventricular, TOF=Tetralogy of Fallot, DCM=Dilated cardiomyopathy, BSA=Body surface area



**Figure 1:** Case of ischemic heart disease in a patient hospitalized for subacute myocardial infarction. (a) Transthoracic echocardiography, apical four-chamber view: dilatation and severe systolic dysfunction of the left ventricle, along with a large apical aneurysm, which is associated with a higher risk of sudden cardiac death. (b) Three-dimensional transthoracic echocardiography allows for a more accurate assessment of biventricular volumes and function. (c) Cardiac magnetic resonance, cine steady state free precession imaging, three-chamber view: the presence of a large apical aneurysm is confirmed. (d) Cardiac magnetic resonance, post contrast imaging, three-chamber view, showing the presence of extensive late gadolinium enhancement at the level of the apical aneurysm.

the heart muscle, thus providing relevant prognostic information.<sup>[5,6]</sup>

This document aims to describe the usefulness of echocardiography and multimodality imaging in the diagnosis and stratification of SCD risk in different clinical scenarios.

**Table 2: Echocardiographic red flags in cardiac amyloidosis and Anderson-Fabry cardiomyopathy**

Cardiac amyloidosis

Thickening of the septum, posterior wall and RV wall

Granular sparkling

Valve thickening

Interatrial septum thickening

Preserved or mildly reduced LVEF

Grade 2 or worse diastolic dysfunction

Enlarged atria

Pericardial effusion (generally small)

Pleural effusion

Abnormal GLS with apical sparing pattern

Anderson-Fabry disease

LV hypertrophy with or without RV hypertrophy

Papillary muscle hypertrophy

Binary sign (echo-bright endocardium with an adjacent hyporeflexive subendocardial layer)

Enlarged atria

Diastolic dysfunction

Abnormal GLS, generally in the inferolateral segments

Valve thickening

Ascending aorta dilatation

GLS=Global longitudinal strain, LV=Left ventricular, LVEF=Left ventricular ejection fraction, RV=Right ventricular


## ISCHEMIC HEART DISEASE

Ischemic heart disease is the leading cause of sudden cardiac death in the general population, particularly among adults and the elderly.<sup>[1,7,8]</sup> Echocardiography is an essential diagnostic tool for evaluating patients with ischemic heart disease, especially for assessing left ventricular systolic function, the presence of valvular abnormalities, and mechanical complications of acute coronary syndromes. Left ventricular ejection fraction is the primary metric used to assess the risk of sudden cardiac death [Flow Chart 1 and Figure 1].<sup>[1,7,8]</sup>

## CARDIOMYOPATHIES

In younger individuals, sudden cardiac death is mainly attributed to cardiomyopathies and primary electrical disorders.<sup>[2]</sup> Echocardiography is the first-line imaging modality in the evaluation of patients with suspected cardiomyopathy, providing valuable information for diagnosis and risk stratification of ventricular arrhythmias and heart failure.<sup>[2]</sup> Assessment of systolic function through the left ventricular ejection fraction remains the cornerstone of risk stratification for adverse events. Other clinical and imaging characteristics have to be considered in a comprehensive, multiparametric approach [Flow Chart 2a, 2b and Figures 2, 3].<sup>[9-20]</sup>

The key factors associated with an increased risk of sudden cardiac death in other nonischemic cardiomyopathies [Figure 3 and Flow Chart 2b].




**Flow Chart 1:** Key factors associated with an increased risk of sudden death in both acute and chronic ischemic heart disease. CMR = Cardiac magnetic resonance, ECG = Electrocardiogram, ECHO = Echocardiography, ICD = Implantable cardioverter-defibrillators, GLS = Global longitudinal strain, LGE = Late gadolinium enhancement, LV = Left ventricular, LVEF = Left ventricular ejection fraction, MD = Mechanical dispersion, MI = Myocardial infarction, MIBG = Metaiodobenzylguanidine, NYHA = New York Heart Association, NSVT = Nonsustained ventricular tachycardia, OMT = Optimal medical therapy, PES = Programmed electrical stimulation, RV = Right ventricular, SCD = Sudden cardiac death, SPECT, = Single-photon emission computed tomography, STEMI = ST-elevation myocardial infarction, VF = Ventricular fibrillation, VT = Ventricular tachycardia, WMA = Wall motion abnormalities


Non-Ischemic Cardiomyopathies				
DCM	NDLVC	ARVC	HCM	RCM
<p><b>Diagnostic criteria</b></p> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>LVEDD <math>\geq 58</math> mm (males) and <math>\geq 52</math> mm (females);</li> <li>LVEDV <math>\geq 75</math> ml/m<sup>2</sup> (males) and <math>\geq 62</math> ml/m<sup>2</sup> (females);</li> <li>LVEF <math>&lt; 50\%</math>.</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Syncope;</li> <li>Heart failure symptoms.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>Burden of ventricular ectopies;</li> <li>NSVT;</li> <li>AV conduction delay/block *for LMNA mutations.</li> </ul> <p><b>PES:</b></p> <ul style="list-style-type: none"> <li>Sustained monomorphic VT.</li> </ul> <p><b>Genetics:</b></p> <ul style="list-style-type: none"> <li>High-risk genotype (LMNA, TMEM43, DSP, RBM20, PLN, FLNC-truncating variants);</li> <li>Gene-specific risk-prediction scores.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>LVEF <math>\leq 55\%</math> after 3 months of OMT, or higher (LVEF <math>&lt; 50\%</math>) if high-risk genotype and 32 additional risk factors, including syncope, LGE, inducible sustained monomorphic VT at PES; if LMNA mutation, estimated 5-year risk of life-threatening VA <math>\geq 10\%</math> and NSVT or LVEF <math>\leq 50\%</math> or AV conduction delay;</li> <li>Reduction in LV GLS and increase in MD.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Presence and location (i.e. septal; ring-like) of LGE.</li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>Signs of denervation on nuclear imaging with <sup>18</sup>F-MIBG *may be considered in selected patients.</li> </ul>	<p><b>Diagnostic criteria</b></p> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Non-ischaemic LV scarring or fatty replacement in the absence of LV dilatation <math>\neq</math> global or regional WMA of isolated global LV hypokinesia without scarring (LVEF <math>&lt; 50\%</math>).</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Syncope;</li> <li>Heart failure symptoms.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>Low voltage QRS;</li> <li>Burden of ventricular ectopies;</li> <li>NSVT.</li> </ul> <p><b>Genetics:</b></p> <ul style="list-style-type: none"> <li>High-risk genotype (LMNA, TMEM43, DSP, DES, RBM20, PLN, FLNC-truncating variants);</li> <li>Gene-specific risk-prediction scores.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>LVEF <math>\leq 55\%</math> after 3 months of OMT, or higher (LVEF <math>&lt; 50\%</math>) if high-risk genotype and additional risk factors.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Presence and location (i.e. septal; ring-like) of LGE.</li> </ul>	<p><b>Diagnostic criteria</b></p> <p><b>Echocardiography or CMR:</b></p> <ul style="list-style-type: none"> <li>Predominantly RV dilatation and systolic dysfunction (with or without LV involvement);</li> <li>RV wall motion abnormalities, including akinesia, dyskinesia (or bulging), and aneurysms.</li> </ul> <p>For other diagnostic criteria (including family history, genetics, ECG abnormalities, arrhythmias, and tissue characterization) the 2010 modified Task Force criteria and/or the 2024 European Task Force consensus should be applied.</p> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Age;</li> <li>Sex;</li> <li>Syncope.</li> </ul> <p><b>ECG:</b></p> <ul style="list-style-type: none"> <li>Number of inverted T-waves;</li> <li>Fragmented QRS;</li> <li>Low voltage QRS.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>Maximum 24 hours PVC count;</li> <li>NSVT.</li> </ul> <p><b>PES:</b></p> <ul style="list-style-type: none"> <li>Sustained monomorphic VT.</li> </ul> <p><b>ECG or Holter monitoring:</b></p> <ul style="list-style-type: none"> <li>Ventricular ectopies with couplets, triplets and NSVT;</li> <li>Complex conduction defects (high-degree AV block, BBB, prolongation or fragmentation of QRS complex), particularly at an early age (<math>&lt; 40</math> years);</li> <li>Abnormal Q-waves.</li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>Signs of denervation of the LV on nuclear imaging with <sup>18</sup>F-MIBG *may be considered in selected patients.</li> </ul>	<p><b>Diagnostic criteria</b></p> <p><b>Echocardiography or CMR:</b></p> <ul style="list-style-type: none"> <li>LV wall thickness <math>&gt; 15</math> mm (or z-score <math>\geq 2</math> in Children) or <math>\geq 13</math> mm in adult first-degree relatives; consider the diagnosis if LV wall thickness 13-14 mm in the presence of other (e.g. family history, genetic findings, ECG abnormalities).</li> </ul> <p><b>Other relevant parameters:</b></p> <ul style="list-style-type: none"> <li>Doppler evaluation of LVOTO at rest, during Valsalva manoeuvre, in the sitting and semi-supine positions, and then on standing if no gradient is provoked (severe if peak gradient <math>\geq 50</math> mmHg).</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Age;</li> <li>Family history of SCD;</li> <li>Syncope.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>NSVT.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>Maximum LV wall thickness;</li> <li>Left atrial diameter;</li> <li>LV outflow tract gradient;</li> <li>Reduction in LV GLS and increase in MD.</li> </ul> <p><b>Additional features to be considered</b></p> <p><b>Echocardiography and/or CMR:</b></p> <ul style="list-style-type: none"> <li>LVEF <math>&lt; 50\%</math>;</li> <li>LV apical aneurysm;</li> <li>Extensive LGE (<math>\geq 15\%</math> of the myocardial mass).</li> </ul> <p><b>Other:</b></p> <ul style="list-style-type: none"> <li>Abnormal systolic blood pressure response to exercise.</li> </ul>	<p><b>Diagnostic criteria</b></p> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>Restrictive LV and/or RV pathophysiology in the presence of normal or reduced diastolic volumes of one or both ventricles, normal or reduced systolic volumes, and normal ventricular wall thickness.</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Female sex;</li> <li>Chest pain;</li> <li>Syncope;</li> <li>Heart failure symptoms.</li> </ul> <p><b>ECG:</b></p> <ul style="list-style-type: none"> <li>Prolonged PR interval and QRS duration;</li> <li>Left bundle-branch block;</li> <li>Signs of myocardial ischemia.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>Acute heart block;</li> <li>Reduced LV systolic function.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>Impaired diastolic function;</li> <li>Reduced LV systolic function;</li> <li>LA dilatation.</li> </ul>

Other Non-Ischemic Cardiomyopathies			
Inflammatory Cardiomyopathies	Cardiac Sarcoidosis	Anderson-Fabry disease	Infiltrative Cardiomyopathies
<p><b>Myocarditis</b></p> <p><b>Diagnostic criteria</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Chest pain;</li> <li>Arrhythmias;</li> <li>Heart failure.</li> </ul> <p><b>ECG *non-specific:</b></p> <ul style="list-style-type: none"> <li>High-grade atrioventricular block;</li> <li>Malignant ventricular tachyarrhythmias;</li> <li>PR-segment depression;</li> <li>Pathological Q-waves;</li> <li>Low voltage/wide complex/fragmented QRS;</li> <li>BBB;</li> <li>ST/T-wave changes;</li> <li>Prolonged QT interval.</li> </ul> <p><b>Echocardiography *non-specific:</b></p> <ul style="list-style-type: none"> <li>LV dilatation;</li> <li>LV pseudo-hypertrophy;</li> <li>LV hypercontractile myocardial areas;</li> <li>LV thrombosis;</li> <li>LV WMA;</li> <li>LV systolic/diastolic dysfunction (including reduction in GLS and GCS);</li> <li>RV dysfunction;</li> <li>Pericardial involvement.</li> </ul> <p><b>Laboratory:</b></p> <ul style="list-style-type: none"> <li>Increased cardiac troponin levels.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>At least 1 T2-based criterion (global or regional increase of myocardial T2 relaxation time or increased signal intensity in T2-weighted images) in addition to <math>\geq 1</math> T1-based criterion (increased myocardial T1 relaxation time, LGE, or ECV), *midwall and/or subendocardial LGE (subendocardial LGE can be observed in combination with nonischemic patterns).</li> </ul> <p><b>PET:</b></p> <ul style="list-style-type: none"> <li>18F-FDG for detection of active myocardial inflammation.</li> </ul> <p><b>EMB:</b></p> <ul style="list-style-type: none"> <li>Presence of inflammatory cells and myocyte necrosis.</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Male sex;</li> <li>Syncope;</li> <li>Heart failure.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>Significant ventricular arrhythmias.</li> </ul> <p><b>Echocardiography and/or CMR:</b></p> <ul style="list-style-type: none"> <li>LVEF <math>\leq 55\%</math>;</li> <li>Reduction in LV GLS.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Presence, location (midwall septal) and extension (<math>\geq 2</math> segments) of LGE, particularly if persistent after resolution of acute inflammation.</li> </ul>	<p><b>Cardiac Sarcoidosis</b></p> <p><b>Diagnostic criteria</b></p> <p>Multisystem chronic inflammatory disease characterized by the presence of non-caseating granulomas and tissue scarring. It may occur in an isolated cardiac form.</p> <p><b>ECG or Holter monitoring:</b></p> <ul style="list-style-type: none"> <li>Ventricular ectopies with couplets, triplets and NSVT;</li> <li>Complex conduction defects (high-degree AV block, BBB, prolongation or fragmentation of QRS complex), particularly at an early age (<math>&lt; 40</math> years);</li> <li>Abnormal Q-waves.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>Thinning of the basal segment of the IVS (basal IVS <math>\leq 4</math> mm and/or basal IVS/IVS ratio <math>\leq 0.6</math>);</li> <li>LVEF <math>&lt; 50\%</math>.</li> </ul> <p><b>Other echocardiographic features:</b></p> <ul style="list-style-type: none"> <li>Mid wall thickening due to edema in any LV segment (mainly basal IVS or inferolateral wall);</li> <li>Regional WMA with non-coronary distribution;</li> <li>Reduction of LV GLS.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Evidence of inflammation using T2-weighted imaging and T1/T2 mapping;</li> <li>Multiple areas of LGE with mixed pattern without coronary distribution (including the typical involvement of the right side of the basal anteroseptum extending into the subepicardium of the RV/LV).</li> </ul> <p><b>PET:</b></p> <ul style="list-style-type: none"> <li>18F-FDG for detection of active myocardial inflammation;</li> <li>Myocardial perfusion scan for detection of scar and/or inflammation.</li> </ul> <p><b>EMB:</b></p> <ul style="list-style-type: none"> <li>Non-necrotizing epithelioid cell granulomas.</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>ECG:</b></p> <ul style="list-style-type: none"> <li>High-degree AV block.</li> </ul> <p><b>Echocardiography and/or CMR:</b></p> <ul style="list-style-type: none"> <li>LVEF <math>\leq 55\%</math>;</li> <li>Reduction in GLS;</li> <li>RVEF <math>&lt; 40\%</math>.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Significant LGE, particularly if persistent after resolution of acute inflammation (in patients with LVEF 35-50%).</li> </ul> <p><b>Programmed electrical stimulation:</b></p> <ul style="list-style-type: none"> <li>Inducibility of sustained monomorphic VT (in patients with LVEF 35-50% and/or minor LGE at CMR).</li> </ul>	<p><b>Anderson-Fabry disease</b></p> <p><b>Diagnostic criteria</b></p> <p>Should be suspected in patients with LVH and additional red flags, such as no male-to-male transmission in pedigree, advanced kidney disease, juvenile stroke/neuropathic pain, gastrointestinal symptoms, cornea verticillata, hearing loss, angiokeratomas.</p> <p><b>ECG:</b></p> <ul style="list-style-type: none"> <li>Bradycardia;</li> <li>Chronotropic incompetence;</li> <li>Short PQ interval in young;</li> <li>AV blocks in adults;</li> <li>LVH.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>LVH;</li> <li>Hypertrophy of papillary muscles;</li> <li>Mitral and aortic valve thickening with mild-to-moderate regurgitations;</li> <li>Reduced GLS.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Basal-inferolateral LGE;</li> <li>Low native T1 (pseudonormalization in fibrotic areas).</li> </ul> <p><b>Laboratory:</b></p> <ul style="list-style-type: none"> <li>Elevated HS-Troponin and NT-proBNP;</li> <li>Reduced α-GalA activity and high lysa-Gb3 in males;</li> <li>GalA genetic analysis in females.</li> </ul> <p><b>Major features associated with an increased risk of SCD</b></p> <p><b>Clinical evaluation:</b></p> <ul style="list-style-type: none"> <li>Age <math>&gt; 40</math> years;</li> <li>Male sex;</li> <li>Syncope;</li> <li>Palpitations.</li> </ul> <p><b>ECG monitoring:</b></p> <ul style="list-style-type: none"> <li>NSVT.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>Increased LV wall thickness;</li> <li>Increased LV mass.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>LGE.</li> </ul>	<p><b>Cardiac Amyloidosis</b></p> <p><b>Diagnostic criteria</b></p> <p>Should be suspected in patients with LVH and additional red flags, such as family history, heart failure and aortic stenosis in patients <math>\geq 65</math> years, bilateral carpal tunnel syndrome, ruptured biceps tendon, hyposthenia, peripheral polyneuropathy, autonomic dysfunction, proteinuria, skin bruising, known multiple myeloma or MGUS.</p> <p><b>ECG:</b></p> <ul style="list-style-type: none"> <li>Decreased QRS voltage to mass ratio;</li> <li>Pseudo Q waves;</li> <li>AV conduction disease.</li> </ul> <p><b>Echocardiography:</b></p> <ul style="list-style-type: none"> <li>LV wall thickness <math>\geq 12</math> mm;</li> <li>Reduced GLS with apical sparing.</li> </ul> <p><b>CMR:</b></p> <ul style="list-style-type: none"> <li>Diffuse subendocardial or transmural LGE;</li> <li>Increased ECV.</li> </ul> <p><b>Laboratory:</b></p> <ul style="list-style-type: none"> <li>Chronically increased troponin levels;</li> <li>Exclusion of a clonal haematological dyscrasia.</li> </ul> <p><b>SPECT (only for ATTR):</b></p> <ul style="list-style-type: none"> <li>Grade 2 or 3 myocardial radiotracer uptake in 99mTc-PYP or DPD or HMDP scintigraphy.</li> </ul> <p><b>EMB (or extracardiac biopsy):</b></p> <ul style="list-style-type: none"> <li>Histopathological demonstration of amyloid fibrils.</li> </ul> <p><b>Major features associated with an increased risk of sudden death</b></p> <p>The natural history is associated with electrical conduction disease and symptomatic bradycardia. The benefit of primary prevention ICD implantation is uncertain.</p>

**Flow Chart 2:** Key factors associated with an increased risk of sudden cardiac death in non-ischemic cardiomyopathies. ARCV = Arrhythmogenic right ventricular cardiomyopathy, AV = Atrio-ventricular, CMR = Cardiac magnetic resonance, DCM = Dilated cardiomyopathy, ECG = Electrocardiogram, HCM = Hypertrophic cardiomyopathy, LA = Left atrial, LGE = Late gadolinium enhancement, LV = Left ventricular, LVEDD = Left ventricular end-diastolic diameter, LVEDV = Left ventricular end-diastolic volume, LVEF = Left ventricular ejection fraction, LVOTO = Left ventricular outflow tract obstruction, MIBG = Metaiodobenzylguanidine, NDLVC = Non-dilated left ventricular cardiomyopathy, NSVT = Nonsustained ventricular tachycardia, OMT = Optimal medical therapy, PES = Programmed electrical stimulation, PVC = Premature ventricular contractions, RCM = Restrictive cardiomyopathy, RV = Right ventricular, RVEF = Right ventricular ejection fraction, SCD = Sudden cardiac death, VA = Ventricular arrhythmia, VT = Ventricular tachycardia, WMA = Wall motion abnormalities, ATTR = Transthyretin amyloidosis, BBB = Bundle branch block, DPD = 3,3-diphosphono-1,2-propanodiphenylacetic acid, ECV = Extracellular volume, EMB = Endomyocardial biopsy, FDG = Fluorodeoxyglucose, GCS = Global circumferential strain, GLS = Global longitudinal strain, HMDP = Hydroxymethylene diphosphonate, HS = High-sensitivity, IVS = Interventricular septum, LVH = Left ventricular hypertrophy, MGUS = Monoclonal gammopathy of undetermined significance, PET = Positron emission tomography, PYP = Pyrophosphate, SCD = Sudden cardiac death, SPECT = Single-photon emission computed tomography



**Figure 2:** Sudden cardiac death risk stratification in the setting of cardiomyopathies, first section. (a-d) Case of dilated cardiomyopathy in a patient with a pathogenic mutation in the FLNC gene; (a) transthoracic echocardiography, apical four-chamber view: dilatation of the left ventricle with severe systolic dysfunction; (b) reduced global longitudinal strain; (c) increased mechanical dispersion; (d) cardiac magnetic resonance, postcontrast imaging, showing presence of late gadolinium enhancement at the level of the inferior wall. (e-i) Case of non-dilated left ventricular cardiomyopathy with preserved left ventricular systolic function in a patient with a pathogenic mutation in DSP gene; cardiac magnetic resonance, postcontrast imaging, shows the presence of extensive late gadolinium enhancement in the inferior, posterior, and lateral walls. (l-n) Case of arrhythmogenic right ventricular cardiomyopathy in a patient with a pathogenic mutation in the PKP2 gene; cardiac magnetic resonance, cine steady state free precession imaging, showing dilatation of the right ventricle with severe systolic dysfunction, along with the presence of large aneurysms in the sub-tricuspidal region and the right ventricular outflow tract. (o-q) Case of obstructive hypertrophic cardiomyopathy; (o-p) transthoracic echocardiography, showing the presence of severe hypertrophy of the interventricular septum and left ventricular outflow tract obstruction due to systolic anterior motion of the mitral valve; (q) transthoracic echocardiography, continuous wave spectral Doppler: evidence of significant left ventricular outflow tract peak systolic gradient.



**Figure 3:** Sudden cardiac death risk stratification in the setting of cardiomyopathies, second section. (a-e) Case of myocarditis in a patient presenting with chest pain; (a-b) cardiac magnetic resonance,  $T_2$ -weighted short-tau inversion recovery imaging, showing signal hyperintensity of the interventricular septum and inferior wall, consistent with the presence of myocardial edema; (c-e) cardiac magnetic resonance, postcontrast imaging, showing extensive areas of intramyocardial and subepicardial late gadolinium enhancement in the same regions. (f-o) Case of cardiac sarcoidosis; (f) transthoracic echocardiography, apical four-chamber view: dilatation and severe systolic dysfunction of the left ventricle; a thinning of the basal interventricular septum can be observed; (g) cardiac magnetic resonance, cine steady state-free precession imaging, confirming the echocardiographic findings; (h) cardiac magnetic resonance,  $T_2$ -weighted short-tau inversion recovery imaging, showing areas of increased signal intensity due to the presence of myocardial edema; (i-n) cardiac magnetic resonance, postcontrast imaging, showing extensive biventricular late gadolinium enhancement with mixed pattern and the typical involvement of the interventricular septum; (o) positron emission tomography, showing high  $^{18}\text{F}$ -fluorodeoxyglucose uptake of the myocardium.


## CONGENITAL HEART DISEASE

Several studies have consistently demonstrated higher rates of SCD among adults with congenital heart disease compared to the general population.<sup>[21]</sup> Patients with repaired tetralogy of Fallot are at increased risk of SCD, primarily due to ventricular arrhythmias. In this context, imaging modalities play a crucial role, and particular attention should be given to left ventricular dysfunction and biventricular scarring.<sup>[22]</sup> Transposition of the great arteries (both congenitally corrected and dextro-transposition of the great arteries following atrial switch repair) is another relevant condition strongly associated with SCD. In these scenarios, systemic right ventricular


dysfunction and moderate-to-severe tricuspid regurgitation are significantly associated with higher risk of events.<sup>[23]</sup> Ebstein anomaly and congenital abnormalities of coronary arteries are also linked to increased risk of SCD.<sup>[24,25]</sup> Finally, in patients with Eisenmenger physiology or incompletely palliated congenital heart disease, arrhythmic risk stratification should be evaluated case by case [Flow Chart 3].

## OTHER RELEVANT CLINICAL CONDITIONS ASSOCIATED WITH INCREASED RISK OF SUDDEN DEATH

Echocardiography is the primary imaging modality for evaluating valvular heart disease.<sup>[26]</sup> In recent years, mitral



**Flow Chart 3:** Key factors associated with an increased risk of sudden cardiac death in congenital heart disease. AAOCA = Anomalous aortic origin of a coronary artery, ACAPA = Anomalous coronary artery from the pulmonary artery, AV = Atrio-ventricular, ccTGA = Congenitally corrected transposition of the great arteries, D-TGA = Dextro-transposition of the great arteries, CMR = Cardiac magnetic resonance, CT = Computed tomography, ECG = Electrocardiogram, FWLS = Free wall longitudinal strain, GLS = Global longitudinal strain, HB = Haemoglobin, LV = Left ventricular, LVEF = Left ventricular ejection fraction, LVOTO = Left ventricular outflow tract obstruction, LGE = Late gadolinium enhancement, NSVT = Non-sustained ventricular tachycardia, RV = Right ventricular, SCD = Sudden cardiac death, TOF = Tetralogy of Fallot, TR = Tricuspid regurgitation, VT = Ventricular tachycardia



1. MVP: systolic displacement of one or both mitral leaflets  $\geq 2$  mm above the plane of the mitral annulus in the sagittal view.
  2. MAD: clear separation between the ventricular myocardium and the mitral annulus supporting the posterior mitral leaflet, in both diastole and systole.
- \* Pseudo-MAD: apparent separation between the posterior mitral valve leaflet and the left ventricular myocardium during systole.

**Flow Chart 4:** Key factors associated with an increased risk of sudden death in other clinical conditions. CMR = Cardiac magnetic resonance, CT = Computed tomography, COPD = Chronic obstructive pulmonary disease, ECG = Electrocardiogram, GLS = Global longitudinal strain, LV = Left ventricular, LVEF = Left ventricular ejection fraction, LGE = Late gadolinium enhancement, MAD = Mitral annular disjunction, MD = Mechanical dispersion, MVP = Mitral valve prolapse, MR = Mitral regurgitation, MV = Mitral valve, NSVT = Non-sustained ventricular tachycardia, PVC = Premature ventricular contractions, SCD = Sudden cardiac death, TWI = T wave inversion, VF = Ventricular fibrillation, VT = Ventricular tachycardia

**Table 3: Major echocardiographic features associated with an increased risk of sudden cardiac death in different clinical conditions**

Acute coronary syndromes
LVEF $\leq 40\%$
RV dysfunction
Ischemic MR
Pericardial effusion
Chronic ischemic heart disease
LVEF $\leq 35\%$ despite $\geq 3$ months of OMT in NYHA II-III class
LVEF $\leq 30\%$ despite $\geq 3$ months of OMT
LVEF $\leq 40\%$ despite $\geq 3$ months of OMT, if NSVT and inducibility of sustained monomorphic VT by PES
DCM
LVEF $\leq 35\%$ after $\geq 3$ months of OMT
LVEF $< 50\%$ if high-risk genotype and $\geq 2$ additional risk factors (i.e. syncope, LGE, and inducible sustained monomorphic VT at PES)
LVEF $< 50\%$ if LMNA mutation
NDLVC
LVEF $\leq 35\%$ after $\geq 3$ months of OMT
LVEF $< 50\%$ if high-risk genotype and additional risk factors (i.e. syncope, LGE, and inducible sustained monomorphic VT at PES)
ARCV
RV fractional area change $\leq 17\%$
LVEF $< 45\%$
HCM
Maximum LV wall thickness
Left atrial diameter
LV outflow tract gradient
RCM
Impaired diastolic function
Reduced LV systolic function
LA dilatation
Anderson-fabry disease
Increased LV wall thickness
Increased LV mass
TOF
LV and RV systolic dysfunction
LV diastolic dysfunction
Reduced LV GLS and RV FWLS
ccTGA and D-TGA
Severe systemic RV dysfunction
Moderate to severe TR
LVOTO $> 36$ mmHg
PAH
Ebstein anomaly
Pulmonic stenosis
LV dysfunction
Congenital anomalies of the origin of a coronary
Left coronary artery arising from the right sinus
High take-off
Arrhythmic mitral valve prolapse
Redundant MV leaflets
MAD
Pickelhaube sign
Severe MR
LVEF $\leq 50\%$

*Contd...***Table 3: Contd...**

Severe aortic valve stenosis
Peak aortic velocity $\geq 5$ m/s
LVEF $< 60\%$ or decline of $15\%$ at follow-up ECHO in asymptomatic patients
Aortic root and ascending aorta dilatation
Diameter $> 50$ mm (high risk if $> 60$ mm)
Growth of the aortic diameter $\geq 3$ mm per year
Root phenotype
ccTGA=Congenitally corrected transposition of the great arteries, D-TGA=Dextro-transposition of the great arteries, FWLS=Free wall longitudinal strain, GLS=Global longitudinal strain, LA=Left atrial, LGE=Late gadolinium enhancement, LMNA=Lamin A/C, LV=Left ventricular, LVEF=Left ventricular ejection fraction, LVOTO=Left ventricular outflow tract obstruction, MAD=Mitral annular disjunction, MR=Mitral regurgitation, MV=Mitral valve, NSVT=Nonsustained ventricular tachycardia, NYHA=New York Heart Association, OMT=Optimal medical therapy, PAH=Pulmonary arterial hypertension, PES=Programmed electrical stimulation, RV=Right ventricular, TR=Tricuspid regurgitation, VT=ventricular tachycardia, HCM=Hypertrophic cardiomyopathy, NDLVC=Nondilated left ventricular cardiomyopathy, TOF=Tetralogy of Fallot, ARCV=Arrhythmogenic right ventricular cardiomyopathy, DCM=Dilated cardiomyopathy, RCM=Restrictive cardiomyopathy, ECHO=Echocardiography

valve prolapse has garnered significant attention due to its potential association with an increased risk of SCD, primarily linked to ventricular arrhythmias, both in patients with and without severe mitral regurgitation.<sup>[27]</sup> Aortic stenosis is an increasingly prevalent valvular disease, largely driven by population aging. Echocardiography remains the cornerstone for both diagnosis and risk stratification.<sup>[26]</sup> Dilatation of the aortic root and ascending aorta is another condition that may be associated with sudden death. Therefore, echocardiographic evaluation of the ascending aorta is essential for early detection and risk stratification [Flow Chart 4].<sup>[28]</sup>

## CONCLUSIONS

SCD remains a major clinical and public health concern. Identifying at-risk patients is challenging and requires a multiparametric approach. Multimodality imaging plays a central role in risk stratification, providing comprehensive insights into biventricular function and detecting tissue abnormalities. Echocardiography serves as the first-line imaging modality for patient assessment, offering precise diagnostic and risk stratification insights.

## Financial support and sponsorship

Nil.

## Conflicts of interest

There are no conflicts of interest.

## REFERENCES

- Zeppenfeld K, Tfelt-Hansen J, de Riva M, Winkel BG, Behr ER, Blom NA, *et al.* 2022 ESC guidelines for the management of patients with ventricular arrhythmias and the prevention of sudden cardiac death. *Eur Heart J* 2022;43:3997-4126.
- Arbelo E, Protonotarios A, Gimeno JR, Arbustini E, Barriales-Villa R,

- Basso C, *et al.* 2023 ESC guidelines for the management of cardiomyopathies. *Eur Heart J* 2023;44:3503-626.
3. Barletta V, Fabiani I, Lorenzo C, Nicastro I, Bello VD. Sudden cardiac death: A review focused on cardiovascular imaging. *J Cardiovasc Echogr* 2014;24:41-51.
  4. Smiseth OA, Rider O, Cvijic M, Valkovič L, Remme EW, Voigt JU. Myocardial strain imaging: theory, current practice, and the future. *JACC Cardiovasc Imaging* 2025;18:340-81.
  5. Porcari A, De Luca A, Grigoratos C, Biondi F, Faganello G, Vitrella G, *et al.* Arrhythmic risk stratification by cardiac magnetic resonance tissue characterization: Disclosing the arrhythmic substrate within the heart muscle. *Heart Fail Rev* 2022;27:49-69.
  6. Faganello G, Porcari A, Biondi F, Merlo M, De Luca A, Vitrella G, *et al.* Cardiac magnetic resonance in primary prevention of sudden cardiac death. *J Cardiovasc Echogr* 2019;29:89-94.
  7. Zwart B, Claessen BE, Damman P, Woudstra P, Vink MA, Balder JW, *et al.* 2023 European Society of Cardiology guidelines for the management of acute coronary syndromes: Statement of endorsement by the NVVC. *Neth Heart J* 2024;32:338-45.
  8. Vrints C, Andreotti F, Koskinas KC, Rossello X, Adamo M, Ainslie J, *et al.* 2024 ESC guidelines for the management of chronic coronary syndromes. *Eur Heart J* 2024;45:3415-537.
  9. Gimelli A, Liga R, Agostini D, Bengel FM, Ernst S, Hyafil F, *et al.* The role of myocardial innervation imaging in different clinical scenarios: An expert document of the European Association of Cardiovascular Imaging and Cardiovascular Committee of the European Association of Nuclear Medicine. *Eur Heart J Cardiovasc Imaging* 2021;22:480-90.
  10. McDonagh TA, Metra M, Adamo M, Gardner RS, Baumbach A, Böhm M, *et al.* 2021 ESC guidelines for the diagnosis and treatment of acute and chronic heart failure. *Eur Heart J* 2021;42:3599-726.
  11. Corrado D, Anastakis A, Basso C, Baucé B, Blomström-Lundqvist C, Bucciarelli-Ducci C, *et al.* Proposed diagnostic criteria for arrhythmogenic cardiomyopathy: European Task Force consensus report. *Int J Cardiol* 2024;395:131447.
  12. Aquaro GD, De Luca A, Cappelletto C, Raimondi F, Bianco F, Botto N, *et al.* Prognostic value of magnetic resonance phenotype in patients with arrhythmogenic right ventricular cardiomyopathy. *J Am Coll Cardiol* 2020;75:2753-65.
  13. Castrichini M, De Luca A, De Angelis G, Neves R, Paldino A, Dal Ferro M, *et al.* Magnetic resonance imaging characterization and clinical outcomes of dilated and arrhythmogenic left ventricular cardiomyopathies. *J Am Coll Cardiol* 2024;83:1841-51.
  14. Radmilovic J, D'Andrea A, D'Amato A, Tagliamonte E, Sperlongano S, Riegler L, *et al.* Echocardiography in athletes in primary prevention of sudden death. *J Cardiovasc Echogr* 2019;29:139-48.
  15. Filomena D, Vandenberk B, Dresselaers T, Willems R, Masci PG, Robyns T, *et al.* Cardiac diagnoses and long-term outcomes in ring-like late gadolinium enhancement evaluated by cardiac magnetic resonance. *Eur Heart J Cardiovasc Imaging* 2025;26:841-52.
  16. Writing Committee, Drazner MH, Bozkurt B, Cooper LT, Aggarwal NR, Basso C, *et al.* 2024 ACC expert consensus decision pathway on strategies and criteria for the diagnosis and management of myocarditis: A report of the American College of Cardiology solution set oversight committee. *J Am Coll Cardiol* 2025;85:391-431.
  17. Sharma R, Kouranos V, Cooper LT, Metra M, Ristic A, Heidecker B, *et al.* Management of cardiac sarcoidosis. *Eur Heart J* 2024;45:2697-726.
  18. Aquaro GD, Perfetti M, Camastra G, Monti L, Dellegrottaglie S, Moro C, *et al.* Cardiac MR with late gadolinium enhancement in acute myocarditis with preserved systolic function: ITAMY study. *J Am Coll Cardiol* 2017;70:1977-87.
  19. Aquaro GD, Ghebru Habtemicael Y, Camastra G, Monti L, Dellegrottaglie S, Moro C, *et al.* Prognostic value of repeating cardiac magnetic resonance in patients with acute myocarditis. *J Am Coll Cardiol* 2019;74:2439-48.
  20. Gentile P, Merlo M, Peretto G, Ammirati E, Sala S, Della Bella P, *et al.* Post-discharge arrhythmic risk stratification of patients with acute myocarditis and life-threatening ventricular tachyarrhythmias. *Eur J Heart Fail* 2021;23:2045-54.
  21. Baumgartner H, De Backer J, Babu-Narayan SV, Budts W, Chessa M, Diller GP, *et al.* 2020 ESC guidelines for the management of adult congenital heart disease. *Eur Heart J* 2021;42:563-645.
  22. Krieger EV, Zeppenfeld K, DeWitt ES, Duarte VE, Egbe AC, Haefele C, *et al.* Arrhythmias in repaired tetralogy of fallot: A scientific statement from the American Heart Association. *Circ Arrhythm Electrophysiol* 2022;15:e000084.
  23. Ladouceur M, Van De Bruaene A, Kauling R, Budts W, Roos-Hesselink J, Albert SV, *et al.* A new score for life-threatening ventricular arrhythmias and sudden cardiac death in adults with transposition of the great arteries and a systemic right ventricle. *Eur Heart J* 2022;43:2685-94.
  24. Attenhofer Jost CH, Tan NY, Hassan A, Vargas ER, Hodge DO, Dearani JA, *et al.* Sudden death in patients with Ebstein anomaly. *Eur Heart J* 2018;39:1970-7a.
  25. Bigler MR, Kadner A, Räder L, Ashraf A, Windecker S, Siepe M, *et al.* Therapeutic management of anomalous coronary arteries originating from the opposite sinus of valsalva: Current evidence, proposed approach, and the unknowing. *J Am Heart Assoc* 2022;11:e027098.
  26. Vahanian A, Beyersdorf F, Praz F, Milojevic M, Baldus S, Bauersachs J, *et al.* 2021 ESC/EACTS guidelines for the management of valvular heart disease. *Eur Heart J* 2022;43:561-632.
  27. Sabbag A, Essayagh B, Barrera JD, Basso C, Berni A, Cosyns B, *et al.* EHRA expert consensus statement on arrhythmic mitral valve prolapse and mitral annular disjunction complex in collaboration with the ESC council on valvular heart disease and the European Association of Cardiovascular Imaging endorsed by the Heart Rhythm Society, by the Asia Pacific Heart Rhythm Society, and by the Latin American Heart Rhythm Society. *Europace* 2022;24:1981-2003.
  28. Mazzolai L, Teixido-Tura G, Lanzi S, Boc V, Bossone E, Brodmann M, *et al.* 2024 ESC guidelines for the management of peripheral arterial and aortic diseases. *Eur Heart J* 2024;45:3538-700.